Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Cancer. 2018 Aug 1;124(17):3596–3608. doi: 10.1002/cncr.31593

Table 1.

Demographic and treatment characteristics of survivors of CNS tumors, solid tumors and siblings

Characteristic CNS Tumor (n=665) Solid Tumor (n=1376) Sibling (n=726) Pa Pb Pc
N (%) Median (Range) N (%) Median (Range) N (%) Median (Range)
Sex Male 358 (53.8) 694 (50.4) 379 (52.2) .15 .54 .44
Female 307 (46.2) 682 (49.6) 347 (47.8)
Age (Year) 15.0 (12.0-17.0) 15.0 (12.0-17.0) 15.0 (12.0-17.0)
Household Income < 40,000 161 (25.8) 331 (25.9) 133 (19.3) .74 .01 <.001
40,000-79,999 199 (31.9) 427 (33.4) 223 (32.3)
>=80,000 264 (42.3) 519 (40.6) 334 (48.4)
Race/Ethnicity White 555 (87.0) 1099 (82.3) 600 (86.3) .009 .56 <.001
Black 31 (4.9) 122 (9.1) 28 (4.0)
Hispanic 35 (5.5) 72 (5.4) 40 (5.8)
Other 17 (2.7) 42 (3.1) 27 (3.9)
Diagnosis Astrocytoma 382 (57.4)
Medulloblastoma, 156 (23.5)
PNET
Other CNS tumors 127 (19.1)
Neuroblastoma 703 (51.1)
Wilms Tumor 673 (48.9)
No cancer 726
Age at Diagnosis (Year) 2.9 (0.0-9.2) 1.5 (0.0-8.4)
Time Since Diagnosis 12.1 (8/0- 13.2 (8.3-
(Year) 17.7) 17.9)
CRT No 291 (48.3) 1192 (95.8) 726 <.0001
Yes 312 (51.7) 52 (4.2)
CRT Dose (Gy) Mean (SD)
Posterior Fossa 20.3 (25.3)
Temporal Lobe 23.0 (25.1)
Frontal Cortex 11.7 (18.0)
Parietal or Occipital 11.2 (17.6)
Lobe
Total Dose 27.0 (26.6)
Decade of Diagnosis 1970-1989 367 (55.94)
1990-1999 293 (44.06)
SMN No 654 (98.3) 1355 (98.5) 726 0.83
Yes 11 (1.7) 21 (1.5)
Relapse No 650 (97.7) 1372 (99.7) 726 <.0001
Yes 15 (2.3) 4 (0.3)

Abbreviations: CNS, central nervous system; CRT, cranial radiation therapy; SMN, secondary malignancy.

a

CNS tumor vs.Solid tumor;

b

CNS tumor vs. Sibling controls;

c

Solid tumor vs. Sibling controls